In the current study, we investigated the potential of a molecular-based therapy for a subgroup of basal-like breast tumors: those arising in women with an inherited mutation in BRCA1. These tumors are characterized by the loss of the second BRCA1 allele, concomitant loss of TP53 function and an undifferentiated, basal-like phenotype [6-9]. This evidence concerns the gene BRCA1 and breast neoplasm.